证券简称：通策医疗 证券代码：600763 编号：临 2025-007 通策医疗股份有限公司 2.行业萎缩与机构退出潮 2024 年全国妇幼专科医院出现大规模市场出清，超 500 家机构终止运营（含 潍坊艾玛妇产医院、宿迁儿童医院等区域标杆），行业供给端收缩幅度达历史峰 值，市场容量同比缩减 23%。 3.生育意愿抑制因素强化 宏观经济不确定性、职业发展机会成本攀升及育儿综合成本高企（占家庭可 支配收入比重超 40%）导致生育意愿持续低迷，妇幼医疗支付能力与需求弹性显 著弱化。 关于确认其他权益工具公允价值变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、本次确认其他权益工具投资公允价值变动情况概述 （一）本次确认其他权益工具投资公允价值变动的原因 根据《企业会计准则第 22 号——金融工具确认和计量》、《上海证券交易 所上市规则》及公司会计政策、会计估计等相关规定，为客观反映资产公允价值 及经营成果，经审慎评估浙江通策壹号投资合伙企业（有限合伙）（以下简称"壹 号基金"）的运营表现，并结合妇幼医疗行业系统 ...

证券简称：通策医疗 证券代码：600763 编号：临 2025-004 一、利润分配方案内容 （一）利润分配方案的具体内容 经中汇会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于上 市公司股东的净利润为人民币 501,426,889.23 元。截至 2024 年 12 月 31 日，公 司母公司报表中期末未分配利润为人民币 1,066,685,178.18 元。经公司第十届 董事会第九次会议审议，公司 2024 年度拟以实施权益分派股权登记日登记的总 股本为基数分配利润。本次利润分配方案如下： 公司拟向全体股东每 10 股派发现金红利 4.5 元（含税）。截至 2024 年 12 月 31 日，公司总股本 447,289,117.00 股，以此计算合计拟派发现金红利 201,280,102.65 元（含税），占本年度归属于上市公司股东的净利润的 40.14%。 如在本公告披露日起至实施权益分派股权登记日期间公司总股本发生变动的，拟 通策医疗股份有限公司 关于 2024 年度利润分配的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确 ...

证券简称：通策医疗 证券代码：600763 编号：临 2025-006 通策医疗股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司拟续聘中汇会计师事务所（特殊普通合伙）担任公司 2025 年度财务和内 部控制审计机构。 上年度末（2024 年 12 月 31 日）签署过证券服务业务审计报告的注册会计师人数： 289 人； 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于杭州， 系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服务业务。 事务所名称：中汇会计师事务所（特殊普通合伙）； 成立日期：2013 年 12 月 19 日； 组织形式：特殊普通合伙； 注册地址：杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室； 首席合伙人：高峰； 上年度末（2024 年 12 月 31 日）合伙人数量：116 人； 上年度末（2024 年 12 月 31 日）注册会计师人数： ...

公司代码：600763 公司简称：通策医疗 通策医疗股份有限公司 2024年度内部控制评价报告 通策医疗股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控 ...

A股医疗服务板块走低，三博脑科跌超12%，华南生物跌停，万邦医药跌超5%，澳洋健康、通策医疗等 跌幅居前。 ...

Overview - The core viewpoint of the article emphasizes the significant growth and transformation in China's hospital management sector, driven by government policies and increasing public health awareness [1][4][11]. Industry Background - The Chinese government has implemented various policies to promote the development of the healthcare industry, encouraging social capital to participate in medical services and advancing a multi-tiered healthcare system [4][11]. - The number of hospitals in China is projected to reach 39,000 by 2024, representing a year-on-year growth of 1.68% [1][9]. - The market size of the hospital management industry is expected to reach 806.28 billion yuan in 2024, with a year-on-year growth of 9.53% [1][11]. Industry Chain - The upstream of the hospital management industry includes medical devices, pharmaceuticals, hospital information management systems, and clinical information systems [7]. - The midstream consists of public hospitals, private hospital groups, and third-party hospital management service providers [7]. - The downstream includes patients and institutions requiring medical services, such as health check-up centers and nursing homes [7]. Current Development - The focus on improving medical quality and safety has led to significant advancements in healthcare services, with a notable increase in both the number of medical institutions and the quality of services provided [9]. - The rise in public health awareness has shifted patient expectations towards a more comprehensive range of services, including preventive care and health management [4][11]. Competitive Landscape - The hospital management industry features a mix of public hospitals, private hospital groups, and third-party service providers, each with distinct operational focuses and market strategies [13]. - Public hospitals are transitioning towards refined operations, while private hospitals emphasize market-driven models and specialized services [13]. - Third-party providers are adopting asset-light models to offer specialized management services, enhancing operational efficiency for hospitals [13]. Representative Companies - Aier Eye Hospital Group, established in 2002, has expanded its network to 881 facilities globally, with a significant presence in China [15]. - Runhua Service Group focuses on hospital logistics and management services, reporting a revenue of 904 million yuan in 2024, with a gross profit margin of 14.15% [17]. Future Trends - Hospitals are expected to enhance patient experience by streamlining processes such as online appointment scheduling and personalized medical services [19]. - There will be a stronger emphasis on cost control and resource optimization to improve operational efficiency amid policy pressures [19].

Core Insights - Tongce Medical's stock closed at 41.4 yuan, down 10.00%, with a rolling PE ratio of 38.02 times and a total market value of 18.518 billion yuan [1] - The average PE ratio for the medical services industry is 45.72 times, with a median of 41.83 times, placing Tongce Medical at 27th in the industry ranking [1] - As of September 30, 2024, the number of shareholders for Tongce Medical increased to 85,980, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Tongce Medical Co., Ltd. specializes in medical services, primarily focusing on oral healthcare [1] - Key facilities include Hangzhou Oral Hospital Group, Ningbo Oral Hospital Group, Sanyue Children's Dentistry, and other Pugongying branches [1] - The company has received multiple accolades, including being named a "China Excellent Management Company" by Deloitte for five consecutive years and ranking in the Zhejiang Merchants National Top 500 for 2022 and 2023 [1] Financial Performance - For the third quarter of 2024, Tongce Medical reported revenue of 2.233 billion yuan, a year-on-year increase of 2.21% [1] - The net profit for the same period was 498 million yuan, reflecting a year-on-year decrease of 2.63% [1] - The sales gross margin stood at 41.82% [1]

通策医疗股份有限公司的主营业务为医疗服务。公司主要产品是口腔医疗服务。公司主要医院为杭州口 腔医院集团、宁波口腔医院集团、三叶儿童口腔、其他蒲公英分院。通策医疗连续五年获得德勤中国评 选的"中国卓越管理公司"、2022年和2023年连续上榜浙商全国500强、2023年获评新浪财经金麒麟"最受 用户信赖的医疗机构"、通策医疗荣获杭州市上城区"行业领军企业"称号、杭州口腔医院集团荣获2023 年杭州市人民政府质量奖。 最新一期业绩显示，2024年三季报，公司实现营业收入22.33亿元，同比2.21%；净利润4.98亿元，同 比-2.63%，销售毛利率41.82%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)27通策医疗42.3841.245.00206.38亿行业平均 52.8647.733.76166.77亿行业中值49.9041.242.8051.60亿1普瑞眼科-185.3323.162.8062.06亿2何氏眼 科-165.9550.881.6732.33亿3迪安诊断-106.4132.041.4098.50亿4光正眼科-95.73227.447.7121.05亿5创新医 疗-92.46-12 ...

Contract Awards - Gree Electric plans to increase its shareholding through Beijing Haihe Interconnection with an investment of between 1.05 billion to 2.1 billion yuan [1] - Topstrong plans to repurchase shares worth between 20 million to 35 million yuan [1] - Dongfang Zirconium's samples have received preliminary recognition from some solid-state battery material manufacturers for research and trial use [1] - Hongqi Chain is developing and innovating a robot unmanned vending system [1] - Jinyinhai recently entered into deep cooperation with Microvast in the solid-state battery field, with no significant impact on the company's performance in the short term [1] - Honghe Technology proposes a special cash dividend of 12.81 yuan per share [1] Shareholding Changes - Yueling Co.'s actual controller is set to change, and the stock will resume trading tomorrow [1] - Jiaozuo Wanfang's control is also set to change [1] - Yongji Co. plans to transfer part of its equity in Xiniu Wang Company [1] Operating Data - Aerospace Intelligent Manufacturing reported a net profit of 791 million yuan for 2024, an increase of 86.77% year-on-year [1] - Zhangyuan Tungsten reported a net profit of 177 million yuan for 2024, an increase of 23.25% year-on-year [1] - Guangdong Expressway A's net profit for 2024 decreased by 4.39% year-on-year, proposing a cash dividend of 5.23 yuan per share [1] - ST Hanma's heavy-duty truck sales in February reached 810 units, a year-on-year increase of 59.76% [1] - Jiangling Motors sold 21,600 vehicles in February, a year-on-year increase of 8.15% [1] - Dong'an Power's engine sales in February were 28,200 units, a year-on-year decrease of 5.16% [1] - Guangzhou Port's cargo throughput in February is expected to be 40.78 million tons, a year-on-year increase of 13.7% [1] - Far East Co.'s subsidiary won contracts worth over 19.09 billion yuan in February [1] - China Shipbuilding's subsidiary Jiangnan Shipyard signed a batch of dual-fuel container ship construction contracts worth approximately 18 billion to 19 billion yuan [1] - Tsinghua Unigroup signed a supply agreement for lithium battery cathode materials with SK On [1] - Fulongma is expected to win five sanitation service projects in February, with a total contract amount of 339 million yuan [1] - Terui De is expected to win a 194 million yuan new energy project [1] - Samsung Medical's wholly-owned subsidiary won a procurement project from Longyuan Power worth 115 million yuan [1] - Zhongcheng Co. is engaged in procurement business related to inverters and other equipment with related parties [1] Major Investments - Guodian Power is investing in the construction of the Dadu River Eagle Rock Level 1 Hydropower Station project [2] - Batian Co.'s subsidiary plans to invest in the expansion and upgrading of three related projects at the Xiaogaozhai Phosphate Mine [2] Other - Wancheng Group's chairman Wang Jiankun has been detained and is under investigation [2] - Yingjixin plans to acquire control of Huimang Micro, with trading suspended from tomorrow [2] - Hangyang Co. plans to issue convertible bonds not exceeding 1.63 billion yuan [2] - Solar Energy's subsidiary plans to purchase real estate for 367 million yuan [2] - GoerTek's subsidiary's H-share filing materials have been accepted by the China Securities Regulatory Commission [2] - Amway's "water-based solvent-free polyurethane composite material key technology" has been selected as one of the first batch of advanced applicable technologies by the Ministry of Industry and Information Technology [2] - Defang Nano's controlling subsidiary is increasing capital and introducing strategic investors [2] - Yuzhong Three Gorges A has terminated the sale of 10% equity in a small loan company [2] - Tianyu Co. received a warning letter from the FDA in the United States [2] - Haixing Power signed a strategic cooperation agreement with Kerun Zhikong to promote transformer products in overseas markets [2] - Bangjie Co.'s subsidiary Yangzhou Bangjie is temporarily suspending production for no more than three months [2] - Zhi Te New Materials signed a strategic cooperation agreement with Quantum Innovation Center and Microscopic Era [2] - Zhongjin Lingnan plans to raise no more than 1.5 billion yuan through a private placement to its controlling shareholder [2]

证券简称：通策医疗 证券代码：600763 编号：临 2024-065 通策医疗股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 通策医疗股份有限公司（以下简称"公司"）独立董事李敏先生于 2024 年 6 月增持计划披露后，通过上海证券交易所（以下简称"上交所"） 集中竞价交易方式增持公司股份 17,400 股，占公司总股本 0.0039%，本 次增持计划已完成。本次增持完成后，李敏先生直接持有公司股份（包 含公司派股数）43,714 股，占总股本的 0.0098%。 2024 年 12 月 24 日，公司收到独立董事李敏先生关于增持公司股份计划实 施情况的通知，现将有关情况公告如下： 一、增持主体的基本情况 1、增持主体：独立董事李敏先生； 2．本次增持后，李敏先生直接持有公司股份 43,714 股，占总股本的 0.0098%。 3、本次增持计划实施期限届满且已实施完毕。 二、本次增持计划及实施结果 关于董事增持公司股份计划完成的公告 2024 年 6 月 26 日公司在上海证券交易所网站 ...